Strontium ranelate

Strontium ranelate (2 g daily) slightly inhibits bone resorption, slightly stimulates bone formation and progressively dose-dependently increases BMD [1,2].

It decreases the incidence of vertebral fractures by about 40 % [1].

During long-term treatment (4 years), strontium ranelate decreased the vertebral fracture incidence by 33 % [3].

Strontium also decreases the incidence of vertebral fractures by 35 % in younger postmenopausal women (aged 65 or less) and by 32 % in the elderly women aged 80 and over [4,5].

Strontium ranelate decreases the incidence of non-vertebral fractures by about 15 % and even more (31%) in the oldest women [7-9].

Post-hoc analyses demonstrated that strontium ranelate decreases the incidence of hip fracture by approximately 40 % in high risk elderly women with severe osteoporosis [8,9].

 

References

1. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
2. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY 2006 Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060-2066
3. Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY 2009 Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663-1673
4. Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP 2008 Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 67:1736-1738
5. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S 2006 Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21:1113-1120
8. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ 2008 Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687-1695
9. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822